Lexicon Pharmaceuticals (LXRX) Cash from Investing Activities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Cash from Investing Activities data on file, last reported at -$70.3 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 273.14% year-over-year to -$70.3 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 98.39% decrease from a year earlier, with the FY2025 full-year figure at $113.0 million, up 834.95% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$70.3 million, down from $4.8 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for LXRX reached as high as $53.7 million in Q4 2024 and fell as low as -$110.2 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$5.5 million across 5 years, with a median of $4.8 million in 2025.
• Across the five-year window, Cash from Investing Activities plunged 19199.0% in 2022 and soared 374.34% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at $24.2 million in 2022, then soared by 114.69% to $51.9 million in 2023, then increased by 3.47% to $53.7 million in 2024, then tumbled by 91.01% to $4.8 million in 2025, then sank by 1554.72% to -$70.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$70.3 million in Q1 2026, $4.8 million in Q4 2025, and $52.1 million in Q3 2025.